The Journal of Clinical Investigation (Jan 2023)

ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models

  • Jie Li,
  • Jingyi Lu,
  • Manman Xu,
  • Shiyu Yang,
  • Tiantian Yu,
  • Cuimiao Zheng,
  • Xi Huang,
  • Yuwen Pan,
  • Yangyang Chen,
  • Junming Long,
  • Chunyu Zhang,
  • Hua Huang,
  • Qingyuan Dai,
  • Bo Li,
  • Wei Wang,
  • Shuzhong Yao,
  • Chaoyun Pan

Journal volume & issue
Vol. 133, no. 2

Abstract

Read online

WEE1 has emerged as an attractive target in epithelial ovarian cancer (EOC), but how EOC cells may alter their sensitivity to WEE1 inhibition remains unclear. Here, through a cell cycle machinery–related gene RNAi screen, we found that targeting outer dense fiber of sperm tails 2–like (ODF2L) was a synthetic lethal partner with WEE1 kinase inhibition in EOC cells. Knockdown of ODF2L robustly sensitized cells to treatment with the WEE1 inhibitor AZD1775 in EOC cell lines in vitro as well as in xenografts in vivo. Mechanistically, the increased sensitivity to WEE1 inhibition upon ODF2L loss was accompanied by accumulated DNA damage. ODF2L licensed the recruitment of PKMYT1, a functionally redundant kinase of WEE1, to the CDK1–cyclin B complex and thus restricted the activity of CDK1 when WEE1 was inhibited. Clinically, upregulation of ODF2L correlated with CDK1 activity, DNA damage levels, and sensitivity to WEE1 inhibition in patient-derived EOC cells. Moreover, ODF2L levels predicted the response to WEE1 inhibition in an EOC patient–derived xenograft model. Combination treatment with tumor-targeted lipid nanoparticles that packaged ODF2L siRNA and AZD1775 led to the synergistic attenuation of tumor growth in the ID8 ovarian cancer syngeneic mouse model. These data suggest that WEE1 inhibition is a promising precision therapeutic strategy for EOC cells expressing low levels of ODF2L.

Keywords